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Abstract  26 
 27 
Background: Zuccagnia punctata Cav. (Fabaceae) and Larrea nitida Cav. (Zygophyllaceae) are 28 
indistinctly or jointly used in traditional medicine for the treatment of fungal-related infections. 29 
Although their dichloromethane (DCM) extract have demonstrated moderate antifungal activities 30 
when tested on their own, antifungal properties of combinations of both plants have not been 31 
assessed previously. 32 
Purpose: The aim of this study was to establish with statistical rigor whether Z. punctata (ZpE) and 33 
L. nitida DCM extract (LnE) interact synergistically against the clinically important fungi Candida 34 
albicans and Candida glabrata and to characterize the most synergistic combinations. 35 
Study design: For synergism assessment, the statistical-based Boik’s design was applied. Eight 36 
ZpE-LnE fixed-ratio mixtures were prepared from four different months of one year and tested 37 
against Candida strains. Lϕ (Loewe Index) of each mixture at different fractions affected (ϕ) 38 
allowed for the finding of the most synergistic combinations, which were characterized by HPLC 39 
fingerprint and by the quantitation of the selected marker compounds.  40 
Methods: Lϕ and confidence intervals were determined in vitro with the MixLow method, once the 41 
estimated parameters from the dose-response curves of independent extracts and mixtures, were 42 
obtained. Markers (four flavonoids for ZpE and three lignans for LnE) were quantified in each 43 
extract and their combinations, with a valid HPLC-UV method. The 3D-HPLC profiles of the most 44 
synergistic mixtures were obtained by HPLC-DAD. 45 
Results: Three over four IC50ZpE/IC50LnE fixed-ratio mixtures displayed synergistic interactions at 46 
effect levels ϕ > 0.5 against C. albicans. The dosis of the most synergistic (Lϕ = 0.62) mixture was 47 
65.96 µg/ml (ZpE = 28%; LnE = 72%) containing 8 and 36% of flavonoids and lignans 48 
respectively. On the other hand, one over four IC50ZpE/IC50LnE mixtures displays synergistic 49 
interactions at ϕ > 0.5 against C. glabrata. The dosis of the most synergistic (Lϕ = 0.67) mixture 50 
was 168.23 µg/ml (ZpE = 27%; LnE = 73%) with 9.7 and 31.6% of flavonoids and lignans 51 
respectively. 52 
Conclusions: Studies with the statistical-based MixLow method, allowed for the finding of the most 53 
ZpE-LnE synergistic mixtures, giving support to a proper joint use of both antifungal herbs in 54 
traditional medicine. 55 
 56 
  57 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
3 
Introduction 58 
In 2012, the Ministry of Science, Technology and Productive Innovation of Argentina has 59 
launched a National Strategic Plan (2012-2015) for developing phytomedicines containing native or 60 
endemic plants based on the previous investigations conducted by research groups of this country.  61 
Our group has already carried out a project devoted to the search for antifungal Latin American 62 
plants (Svetaz et al. 2010) and also to the isolation of their main antifungal components (Escalante 63 
et al. 2008; Pacciaroni et al. 2008; Derita et al. 2009; Vila et al. 2010; López et al. 2011; Fernández 64 
et al. 2014; and others). Among the tested antifungal plants, two species, Zuccagnia punctata Cav. 65 
(Fabaceae) (Ulibarri 1999, 2005) and Larrea nitida Cav. (Zygophyllaceae) showed moderate 66 
antifungal properties against clinical important fungi (Svetaz et al. 2007; Agüero et al. 2010, 2011; 67 
Alvarez et al. 2012; Nuño et al. 2014).  68 
Z. punctata (common names ‘‘jarilla macho’’, ‘‘jarilla de la puna’’, ‘‘laca’’ or ‘‘pus-pus’’) is a 69 
monotypic species (Ulibarri 2005) currently used in traditional medicine for bacterial and fungal 70 
infections. Moreover, this species can also be used for other pathologies like asthma, arthritis, 71 
rheumatism and tumors (Ratera and Ratera 1980). During many years, Z. punctata has been 72 
described as growing in Chile and Argentina (Ulibarri 1999). However, a thorough study based on 73 
its botanical and bibliographic collections, allowed to demonstrate that the shared distribution with 74 
Chile was erroneous and thus it was firmly established that Z. punctata is endemic of Argentina 75 
(Ulibarri 2005). 76 
Among the different extracts previously tested for antifungal properties, the dichloromethane 77 
(DCM) extract (ZpE) was the most active one (Svetaz et al. 2007; Agüero et al. 2010). This extract 78 
led to the isolation of several compounds of which 5,7-dihydroxi-3-flavonol (galangin, 1), 5,7-79 
dihydroxiflavanone (pinocembrin, 2) and 2’,4’-dihydroxychalcone (3) showed antifungal properties 80 
while 2’,4’-dihydroxy-3’-methoxychalcone (4) (Fig. 1) was the most abundant (though inactive) 81 
compound. The other compounds did not show significant activity in concentrations up to 250 82 
µg/ml. 83 
In turn, the native plant L. nitida (common names “jarilla de la sierra” and “jarilla fina”) (Del 84 
Vitto et al. 1997) is one of the four South American species of Larrea genus (Timmermann et al. 85 
1979) that grows in Argentina and Chile (Hunziker 2005). Antioxidant and antifungal activities 86 
were previously reported for this species (Torres et al. 2003; Agüero et al. 2011), being the DCM 87 
extract (LnE) the most active one. Its bioassay-guided fractionation led to the isolation of five 88 
lignans of which only three, nordihydroguaiaretic acid (NDGA, 5), 4-[4-(4-hydroxy-phenyl)-2,3-89 
dimethyl-butyl]-benzene-1,2-diol (DNDGA, 6) and 3´-O-methyl-nordihydroguaiaretic acid 90 
(MNDGA, 7) (Fig. 1) showed moderate antifungal properties (Agüero et al. 2011). 91 
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INSERT FIG. 1 92 
Although L. nitida is less abundant and grows in more restricted regions, it is indistinctly or 93 
conjunctly used with Z. punctata due to their similar morphological characteristics and also to their 94 
common name (jarilla) (Del Vitto et al. 1997). However, until now, their combinations were used 95 
in an empirical basis, as no mixtures have been scientifically assessed by their type of interaction. 96 
The use of bi-herbal mixtures for the treatment of a disease is a common practice in traditional 97 
medicine (Wagner and Ulrich-Merzenich 2009) in the belief that they may achieve a better 98 
therapeutic effect (synergism) than when used independently (Sibandze et al. 2010). However, 99 
antagonistic or additive effects can be also found between the components of a plant combination 100 
(Williamson 2001; Odds 2003). 101 
The study of antifungal interactions between two extracts is a complex task. The fungi target, the 102 
ratio between extracts in the mixture and the methodology for quantifying synergism must be 103 
chosen carefully in order to achieve trustworthy conclusions. In addition, since extracts are complex 104 
mixtures that usually present seasonal variations, several characterized batches must be combined in 105 
order to get quantified mixtures that display the highest synergism.  106 
In this paper we report the study of the antifungal behavior of four bi-herbal ZpE-LnE 107 
combinations, each of them prepared by mixing one sample of ZpE with one sample of LnE 108 
collected in a same period of a year. This was made for the four periods in which the plants were 109 
collected.  110 
Candida albicans and Candida glabrata were used as targets for the antifungal evaluation. The 111 
choice of C. albicans was due to this yeast is the most common cause of opportunistic fungal 112 
infections in immune compromised hosts (Pfaller and Diekema 2007). In turn, the selection of C. 113 
glabrata was made for it has been identified as the second leading cause of adult candidemia 114 
particularly in patients with hematologic malignancies (Malani et al. 2005; Pfaller and Diekema 115 
2007). 116 
Among the several mathematical methods to quantify synergism that have been proposed over 117 
the last few decades (Berembaum 1989; Merlin 1994; Greco et al. 1995; Tallarida 2001; Chou 118 
2006; Boik et al. 2008), here we chose the Mixed-effects Loewe (MixLow) method (Boik et al. 119 
2008) to determine the Loewe Index (Lϕ) previously defined as Combination Index (CI) within the 120 
Median-effect method (Chou 2006). Both the MixLow and the Median-effect methods share the 121 
following characteristics: (i) assess the data from single ray fixed-ratio experiments; (ii) allow the 122 
identification of the optimal concentration (within the fixed-ratio) that will give the maximum 123 
synergy; (iii) present the results in a graphical form. However, MixLow method has the advantage 124 
over the Median-effect that it allows for the statistically comparison of the combinations’ effects by 125 
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providing accurate dose-response curves’ parameters and confidence intervals for Lϕ that are vital 126 
to fully assess whether drugs in a mixture interact synergistically, antagonistically or additively. 127 
As a result of this study, we could determine the Lϕ of each mixture at different effects (ϕ), and 128 
the composition of the extracts in the two most synergistic ZpE-LnE combinations against each 129 
fungus. The content of the selected markers in both combinations was determined by HPLC-UV 130 
following the International Conference on Harmonization guidelines (ICH 1996). The 3D-HPLC 131 
profiles of both synergistic combinations were provided too.  132 
Materials and methods 133 
Plant material 134 
Aerial parts (AP) of Z. punctata and L. nitida (www.theplantlist.org) were collected over four 135 
periods of 2013 (February, May, September and November) at Las Flores and Bauchaceta towns, 136 
Agua Negra pathway, Iglesia district, San Juan province (Argentina), respectively. The plants were 137 
identified by Dr. Martin Hadad, Instituto de Biotecnología (IBT), Universidad Nacional de San Juan 138 
(UNSJ) and each batch was deposited at the herbarium of the IBT-UNSJ and identified as ZpLF 139 
AT-IBT 02 (abbreviated as ZpE Feb), ZpLF AT-IBT 05 (ZpE May), ZpLF AT-IBT 09 (ZpE Sept), 140 
and ZpLF AT-IBT 11 (ZpE Nov), LnBau AT-IBT 02 (LnE Feb), LnBau AT-IBT 05 (LnE May), 141 
LnBau AT-IBT 09 (LnE Sept) and LnBau AT-IBT 11 (LnE Nov). 142 
Preparation of extracts 143 
ZpEs and LnEs were obtained by dipping fresh AP (500g) in cold DCM (3 x 1l) at room 144 
temperature for 40 s. The solutions were evaporated under vacuum to give semisolid yellow 145 
residues (ZpE Feb, 65 g, 13% w/w yield; ZpE May, 55 g, 11%; ZpE Sept, 60 g, 12%; ZpE Nov, 50 146 
g, 10%. LnE Feb, 50 g, 10%; LnE May, 42.5 g, 8.5%; LnE Sept, 45 g, 9% and LnE Nov, 49 g, 147 
9.8%). 148 
Source of markers 149 
ZpE’s markers galangin (1) and pinocembrin (2) and LnE’s marker NDGA (5) were purchased 150 
from Sigma-Aldrich (St. Louis, MO, USA). Instead, 2’,4’-dihydroxychalcone (3), 2’,4’-dihydroxy-151 
3’-methoxychalcone (4) and MNDGA (7) were obtained in our laboratory from ZpE or LnE as 152 
previously described (Svetaz et al. 2007; Agüero et al. 2010, 2011). The purities of reference 153 
compounds were ≥ 95% as determined by HPLC-DAD. 154 
Preparation of extracts’ and markers’ solutions 155 
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Acetonitrile (ACN) solutions of ZpE and LnE from Feb, May, Sept and Nov and of 1-7 were 156 
prepared at an appropriate concentration, filtered through a 30 mm, 0.45 µm Target Nylon 157 
Membrane Syringe Filter (Scientific Instrument Services, Ringoes, NJ) prior to injection into the 158 
HPLC system. 159 
HPLC-ESI-MS/MS analyses 160 
HPLC-ESI-MS/MS analyses of all batches of ZpE and LnE were carried out by using a 161 
MicroTOFQ II apparatus (Bruker Daltonics, MA, USA), equipped with an ESI ion source with 162 
nitrogen as nebulizing gas (4 psi) and drying gas (8 l/min, 200 °C); capillary 4500 V and end plate 163 
offset at 500 V. Mass accuracy was verified by infusing a 10 mM solution of Na-formiate (Sigma-164 
Aldrich) dissolved in MeOH:H2O (50:50) and a C18-RP column Thermo Scientific (USA) Hypersil 165 
Gold (50 x 2.1 mm, 3 µm). Firstly, pure compounds were characterized by direct infusion to ESI 166 
using a syringe pump (Harvard Apparatus 11 Plus) recording both MS and MS/MS spectra. 167 
Because of the improved performance reached using direct infusion to ESI, we report only MS and 168 
MS/MS data obtained in the negative mode. Reference compounds and sample solutions were 169 
introduced in the HPLC (5 µl) using an autosampler (Agilent HiP-ALSSL+) at 25 °C. Flow rate 170 
was set to 0.20 ml/min and 0.25 ml/min for ZpE and LnE samples and their own reference 171 
compounds, propelled by an Agilent 1200 series G1312B SL binary pump, using ultra-pure water 172 
or HPLC-grade ACN with 0.1% formic acid (solutions A and B respectively) following different 173 
methods: for ZpE extracts and reference compounds, the gradient started with 20% B, changing to 174 
100% B within 10 min, then the composition was held 2 min, returning to 20% B in 3 min and 175 
keeping this condition for additional 5 min to achieve the column stabilization before the next run 176 
(total run time was 20 min). Eluted compounds were monitored at 254 nm. For LnE extracts and 177 
reference compounds, the program started with 40% B, changing to 45% B within 10 min, and to 178 
100% B the following 5 min, held by 4 min and returning to 40% B in 1 min (total run time 20 179 
min). Eluted compounds were monitored at 280 nm. The HPLC flow was introduced into the Mass 180 
spectrometer via an ESI source. For the analyses of chromatograms and mass spectra, the Data 181 
Analysis 4.0 SP1 software (Bruker Daltonik GmgH, Germany) was used. Compounds 1-7 were 182 
identified by comparing their retention times (Rt), HRMS and MS/MS with those of reference 183 
compounds (Agüero et al. 2010, 2011). Markers´ content was quantified in the extracts of the 184 
different periods using the HPLC-UV chromatograms. Five calibration curves of pure compounds 185 
1-5 were prepared with five appropriate dilutions of stock ACN solutions by triplicate. To monitor 186 
the samples, the wavelengths were chosen according to absorption maxima of markers: 267 nm (1), 187 
289 nm (2), 341 nm (3 and 4) and 280 nm (5). 188 
Method validation 189 
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Analytical method´s linearity, limit of detection and quantification (LOD and LOQ) and inter-190 
day / intra-day precision were validated following the ICH guidelines (ICH 1996). Recovery was 191 
used to evaluate the accuracy of the method.  192 
Strains used for the antifungal assessment of extracts and mixtures 193 
For the antifungal evaluation of independent extracts and their combinations, clinical isolates of 194 
C. albicans (CCC 125) and C. glabrata (CCC 115) provided by Centro de Referencia en Micología 195 
(CEREMIC, CCC, Rosario, Argentina), were used. Strains were grown on Sabouraud-196 
chloramphenicol agar slants for 48 h at 30 °C, maintained on Sabouraud-Dextrose Agar (SDA, 197 
Oxoid) and sub-cultured every 15 days to prevent pleomorphic transformations. Inocula were 198 
adjusted to 1-5 x 103 cells with colony forming units (CFU)/ml according to the Clinical and 199 
Laboratory Standards Institute (CLSI 2008). 200 
Synergism studies design 201 
The nature of the interaction between ZpE and LnE in the presence of either C. albicans or C. 202 
glabrata inoculum, was analyzed by the Lϕ (CI) defined by Eq. (1).  203 
Lϕ	 ൌ ICx	ܼ݌E	in	mixtureICx	ܼ݌E	alone ൅	
ICx	ܮ݊E	in	mixture
ICx	ܮ݊E	alone ሺ1ሻ 
Where ICx is the inhibitory concentration used to achieve X% effect (measured as diminution of 204 
fungal growth) of each extract alone and in the mixture. The estimation of Lϕ (Boik et al. 2008) was 205 
a three-step (a-c) process (Scheme 1): (a) preparation of dose-response curves for each extract alone 206 
and for their combinations at a wide range of concentrations. Estimation of parameters that define 207 
the shape of each dose-response curve by using a non-linear regression model (outlined in Scheme 208 
1, a1, a2); (b) use of the estimated parameters for calculating Lϕ; (c) generation of confidence 209 
intervals for Lϕ. 210 
INSERT SCHEME 1 211 
 212 
Dose-response curves of the independent extracts against Candida strains 213 
Broth microdilution techniques were performed in 96-well microplates according to the 214 
M27-A3 document of CLSI for yeasts (CLSI 2008). Each plate was designed as follows (Boik 215 
et al. 2008): 10 different concentrations of each extract (wells 3-12, Fig. 2), by sextuplicate 216 
(wells A-F, Fig. 2) were prepared [T wells (= 60), Fig. 2] from DMSO (maximum 217 
concentration ≤ 1%) 0stock solutions of each extract, diluted with RPMI-1640. In addition, 36 218 
control wells [12 treatment control growth wells (TC) containing culture medium plus 219 
inoculum; 4 medium control wells (MC) (culture medium plus water) and 20 blanks-by-tray 220 
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control wells (BT) (extracts plus water)] were included in the plate (Fig. 2). Each assay was 221 
repeated thrice. So, 18 replicates of each concentration (i.e. (3A-3F) x3; (4A-4F) x3, and so 222 
on) were prepared. 223 
INSERT FIG. 2 224 
In each plate, ZpE and LnE concentrations ranges were selected in order to cover growth 225 
percentages within 95-5% range. To better distribute the points in x-axis, and therefore obtain 226 
a better adjustment of the sigmoidal curve, equi-spaced concentrations in the logarithmic 227 
scale (ln) were prepared (Table S1 of Supplementary Material). An inoculum suspension (100 228 
μl) was added to each well (final well volume = 200 μl) and plates were incubated 24 h at 28-229 
30 ºC in a moist dark chamber. After incubation, the wells’ absorbance values were recorded 230 
at 405 nm with a VERSA Max microplate reader (Molecular Devices, Sunnyvale, CA, USA) 231 
and introduced in the MixLow package of R software (Boik and Narasimhan 2010). Dose-232 
response curves modeled as a sigmoidal function of responses ௗܻ,௧,௪ (y-axis) and extracts’ 233 
concentrations (c) (x-axis) (Eq. 2 and 3) were generated. 234 
ௗܻ,௧,௪ ൌ expሺߤ ൅ ܾ௧ሻ ൫1 െ ߶ௗ,௪,௧൯ ൅ ߳ௗ,௧,௪ሺ2ሻ 
where 235 
߶ௗ,௧,௪ ൌ 1 െ 1
1 ൅ ൬ୣ୶୮൫௖೏,೟,ೢ൯ୣ୶୮൫ట೏,బ.ఱ൯൰
ఊ೏ ሺ3ሻ 
ϕ = E[Fa], where Fa (fraction affected) represents the fraction of fungi affected by an extract at a 236 
concentration c, and E[] is the expected value; cd,t,w refers to the log of the extract’s concentration 237 
for the d (dth extract), t (tth tray), w (wth well) that is a known value. Each sigmoidal curve is 238 
parameterized by three constants: ߰ௗ,଴.ହ, ߛௗ and µ (Scheme 1, a1). The parameter ߰ௗ,଴.ହ		is the log 239 
concentration of each extract that produce a ϕ	= 0.50 (50% inhibition relative to controls). By 240 
convention, exp(߰ௗ,଴.ହ) is called the IC50; ߛௗ	is a shape parameter and µ is the mean of control wells 241 
from all trays (Boik et al. 2008). 242 
Dose-response curves of mixtures against Candida strains 243 
Mixtures of ZpE and LnE were prepared by mixing the mass that produces an equipotent effect 244 
of each partner, in the fixed ratio IC50ZpE/IC50LnE and submitted to antifungal evaluation in 96-245 
wells microplates with the same experimental design of independent extracts. In brief, within each 246 
plate, 10 different concentrations of each fixed-ratio were prepared (Table S2 of Supplementary 247 
material). Each sigmoidal curve is parameterized by three constants:	߰௠,଴.ହ, ߛ௠ and µ (Scheme 1, 248 
a2). 249 
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Quantification of synergism 250 
Once obtained the estimated parameters from the dose-response curves of the independent 251 
extracts (߰ௗ,଴.ହ and ߛௗ) and mixtures (߰௠,଴.ହ and.ߛ௠), the MixLow package can calculate the Lϕ at 252 
different ϕ effects using Eq. (4). 253 
ܮథ ൌ ∑ ߬ௗ exp ቆlog ቆቀ థଵିథቁ
ଵ/ఊ೘ቇ ൅ 	߰௠,଴.ହ െ log ቆቀ థଵିథቁ
ଵ/ఊ೏ቇ െ ߰ௗ,଴.ହቇ௡ௗୀଵ  (4) 254 
where τd is the fraction of the mixture that is composed of extract d. 255 
The confidence intervals for the Lϕ at different ϕ	are calculated with Eq. (5).  256 
expሺlog	ሺ Lமሻ േ	ݐௗ௙,ଵିഀమSEሺlog Lமሻሻ	 (5) 257 
Dose Reduction Index (DRI) 258 
The DRI is a measure of how many times the dose of each drug in a synergistic combination is 259 
reduced at a given effect level compared with the doses of each independent drug. The DRI value 260 
for each drug is calculated using Eq. 6 (Chou 2006). A greater DRI indicates a greater dose 261 
reduction for a given effect level. 262 
DRI ൌ ICx	extract	aloneICx	extract	in	mixture	ሺ6ሻ 
3D-HPLC profile 263 
The most synergistic mixtures were dissolved in ACN, filtered by a membrane filter and 264 
subjected to HPLC analysis in a Hewlett Packard 1050 (Palo Alto, CA), coupled to a DAD detector 265 
(HP/Agilent series 1050 DAD), with a quaternary pump and autosampler (HP/Agilent series 1050) 266 
and Luna C18-RP column (Phenomenex) of 25 cm x 4.6 mm, 5 µm of particle size. The isocratic 267 
solvent phase was composed of ultra-pure water supplemented with formic acid 0.1% (40%) and 268 
HPLC-grade ACN (60%). The flow rate was 0.5 ml/min and the injection volume, 5 µl. Peaks in 269 
the extracts, monitored at λ = 254 nm, were assigned based on the Rt of reference compounds. 270 
Statistical analysis 271 
Statistical analysis was performed with GraphPad PrismTM 4.0 (GraphPad software Inc., La 272 
Jolla, CA). The data were analyzed using both, Kruskal-Wallis test (non-parametric ANOVA) and 273 
Dunn test to verify the difference between treatments; p values < 0.05 were considered significant. 274 
Results and discussion 275 
Markers for HPLC analyses 276 
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The choice of markers 1-7 (Fig. 1) was based on our previous reports. Flavonoids 1-3 and 277 
lignans 5-7 were considered active markers (EMEA 2007) due to they previously showed to be the 278 
main anti-Candida constituents of ZpE and LnE respectively (Svetaz et al. 2007; Agüero et al. 279 
2010, 2011) and 4 was considered an analytical marker (EMEA 2007) since, although inactive, it 280 
was present in high amounts in ZpE (Agüero et al. 2010).  281 
HPLC fingerprints of ZpE and LnE batches 282 
HPLC fingerprints of ZpE and LnE batches (Feb, May, Sept and Nov), are shown in Fig. 3; 1-4 283 
and 5-7 were unequivocally identified (Rt, HRMS and MS/MS data) (Table 1) in each batch of 284 
ZpE, and LnE respectively (Agüero et al. 2011). 285 
INSERT FIG. 3 and TABLE 1 286 
Quantitative assessment of markers in ZpE and LnE batches 287 
The quantification of 1-4 and 5-7 was made by HPLC-UV in each batch of ZpE or LnE 288 
respectively. HPLC method was first validated for linearity, LOD and LOQ, precision and accuracy 289 
following ICH guidelines (ICH 1996), with compounds 1-5. Compounds 6 and 7 of LnE were 290 
quantified by the relative response factors (Gao et al. 2009) based on the calibration curve of 5. 291 
Linearity and calibration curves: Linearity of pure 1-5 calibration curves was established by 292 
calculating the slope, intercepts and R2 coefficient. The regression equation and R2 (0.99-1) showed 293 
good linearity response in the ranges detailed in Table 2. LOD and LOQ were calculated as 3.3 /S 294 
and 10 /S respectively, being  the response standard deviation, and S the slope of each marker. 295 
Precision: Intra- and inter- day variability test was determined for three times within 1 day and 3 296 
separated days at three different concentrations, respectively. Variations were expressed by the 297 
relative standard deviations (RSD) (Table 2), confirming the precision of the proposed method. 298 
Accuracy: Three concentrations of pre-analyzed sample solutions were spiked with known 299 
quantities of the standards and injected in triplicate to perform recovery studies. The percentage 300 
recovery for 1-5 were between 90.6-106.6% (RSD < 4%, n = 3), confirming the accuracy of the 301 
proposed method. 302 
INSERT TABLE 2 303 
Results of quantitative analyses of markers in the eight extracts are shown in Table 3. 304 
INSERT TABLE 3 305 
The non-parametric Kruskall-Wallis test found significant differences between the medians of 306 
markers content (data not shown) for all the periods (p < 0.05). The Dunn test showed statistically 307 
significant differences (p < 0.05) in: (a) the content of 1, 2 and 4 between ZpE Feb and ZpE May; 308 
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(b) the content of 3 between ZpE Sept and ZpE Nov; (c) the content of 5 and 7 between LnE Feb 309 
and LnE Nov and (d) the content of 6 between LnE May and LnE Nov. This variation in markers’ 310 
composition among batches justified the preparation of mixtures with each of them, since the 311 
interactions would be different. 312 
Statistically supported synergism assessment by using fixed-ratio mixtures  313 
Each ZpE or LnE batch was tested against the yeasts C. albicans and C. glabrata in 96-wells 314 
microplates prepared as explained in Materials and Methods (Fig. 2).  315 
With the absorbance values obtained from 18 replicates of each concentration, a sigmoidal dose-316 
response curve for each ZpE or LnE batch was constructed and analyzed with the MixLow method, 317 
which gave the estimated parameters ߰ௗ,଴.ହ [and thus exp(߰ௗ,଴.ହ) = IC50], ߛௗ	 and µ, which are 318 
shown in Table S3. Table 4 (columns 3 and 4) shows the IC50 values of each extract against each 319 
fungus. 320 
INSERT TABLE 4 321 
Ten different concentrations of each IC50ZpE/IC50LnE fixed-ratio mixture were prepared 322 
according to Materials and Methods (Table 4, column 5). Each fixed-ratio concentrations’ set can 323 
be regarded as a ray, in a so-called “ray design”. All sets were tested against either C. albicans or C. 324 
glabrata in 96-wells plates following the same design used for the independent extracts. After 325 
incubation, the absorbance values were introduced in the MixLow package of R software 326 
generating sigmoidal dose-response curves and the corresponding parameters ߰௠,଴.ହ, ߛ௠ and µ for 327 
all combinations (Table S3). Fig. 4 and 5 (A,B,C,D) show the dose-response curves obtained for 328 
ZpE and LnE on their own and in fixed-ratio combinations against C. albicans and C. glabrata 329 
respectively in the four periods of the year. In Fig. 4 and 5 (A’B’C’D’) the affected fraction of 330 
yeasts’ population at a giving drug concentration ϕ was plotted vs the Loewe Index Lϕ. In these 331 
graphs, full lines indicate the Lϕ at different ϕ for a given mixture and dotted lines indicate the 332 
ninety-five percent confidence intervals of the index. Lϕ = 1 indicates additivism (Ad) or no 333 
interaction; Lϕ  1 indicates antagonism (An) and Lϕ < 1 indicates synergism (S) (Boik et al. 2008; 334 
Liu et al. 2013). Within values of Lϕ < 1, the lower Lϕ, the greater synergism (Chou 2006). As 335 
previously suggested (Chou 2006), Lϕ = 0.91-1.09 represents near (n)Ad; Lϕ = 0.85-0.90, slight 336 
(sl)S; 0.70-0.84, moderate (m)S; 0.30-0.69, medium (med)S; 0.10-0.29 strong (s)S and < 0.1, very 337 
strong (vs)S; 1.10-1.20 slight (sl)An; 1.21-1.45 moderate (m)An; 1.46-3.30 medium (med)An; 3.40-338 
10, strong (s)An and 10 very strong (vs)An.  339 
INSERT FIG. 4 AND 5 340 
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In Fig. 4 (A’-D’), it is clear that, when acting against C. albicans, all ZpE-LnE mixtures showed 341 
some degree of synergism in the following ϕ ranges: 0.02 ≤ ϕ ≤ 0.74 (Feb); 0.02 ≤ ϕ ≤ 0.94 (May); 342 
0.50 ≤ ϕ ≤ 0.94 (Sept.) and 0.06 ≤ ϕ ≤ 0.94 (Nov.). In turn, when acting against C. glabrata (Fig. 5, 343 
A´-D’), ZpE-LnE Feb and May mixtures showed synergism in the ϕ ranges: 0.40 ≤ ϕ ≤ 0.94 and 344 
0.02 ≤ ϕ ≤ 0.49 respectively, while ZpE-LnE Sept and Nov mixtures showed antagonism (Lϕ   1) at 345 
all ϕ. For the sake of clarity, the Lϕ values and confidence intervals for ϕ = 0.50, 0.80, 0.90 and 0.95 346 
extracted from Fig. 4 and 5 (A’-D’) are recorded in Table 5. 347 
INSERT TABLE 5 348 
Table 5 clearly shows that the ZpE-LnE May mixture was the most synergistic against C. 349 
albicans, displaying the lowest Lϕ values = 0.62, 0.65 and 0.68 [(med)S] at ϕ = 0.80-0.95. It also 350 
showed (m)S with Lϕ = 0.73 at ϕ = 0.50 against this clinically important fungus. 351 
Instead, C. glabrata was less sensitive to the tested mixtures. The only combination that showed 352 
synergism was that of Feb, which achieved a Lϕ= 0.67 [(med)S] when ϕ = 0.95, and Lϕ= 0.71 or 353 
0.77 [(m)S] at ϕ = 0.90 or 0.80. Interesting enough, all mixtures of May, Sept and Nov showed 354 
(n)Ad or (sl) or (m)An, but none of them showed S. 355 
Composition of synergistic mixtures at different effects levels and DRI values 356 
For the most synergistic mixtures (ZpE-LnE May for Ca and ZpE-LnE Feb for Cg), the 357 
concentrations of each extract in each mixture were calculated using Eq. (2) and (3) (see Materials 358 
and Methods) at ϕ = 0.50, 0.80, 0.90 and 0.95. Table 6 shows that for achieving an effect level of 359 
ϕ= 0.95 against C. albicans, the sum of ZpE and LnE in the mixtures should be 65.96 µg/ml 360 
(column III), composed by 18.84 µg/ml of ZpE (column IV) and 47.12 µg/ml of LnE (column V). 361 
Instead, for achieving lower ϕ (0.9, 0.8 and 0.5), the sum of ZpE and LnE doses were 57.70 µg/ml 362 
(ZpE: 16.48 and LnE: 41.22 µg/ml); 49.91 (ZpE 14.26 and LnE 35.65 µg/ml) and 38.94 µg/ml (ZpE 363 
11.80 and LnE 27.14 µg/ml) respectively. Instead, for achieving an effect level of ϕ = 0.95 against 364 
C. glabrata, the sum of ZpE and LnE concentrations in the mixtures should be 168.23 µg/ml 365 
(column III) composed by 45.47 µg/ml of ZpE (column IV) and 122.76 µg/ml of LnE (column V). 366 
In addition, for lower ϕ (0.90, 0.80 and 0.50), their ZpE and LnE doses are also higher (158.56, 367 
148.69 and 133.22 µg/ml) than those needed for inhibiting C. albicans. 368 
INSERT TABLE 6 369 
DRI values were calculated for different ϕ from Eq. 6. As shown in Table 6 (columns VII and 370 
VIII), ZpE in combination with LnE improved 2.66 and 1.29-fold (= DRI values) the capability of 371 
inhibition of 50% or 80% of C. albicans growth compared to when acting on their own (IC50 and 372 
IC80 decreased from 31.40 to 11.80 µg/ml and from 45.91 to 14.26 µg/ml respectively, columns I 373 
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and IV). Interestingly, IC90 and IC95 diminished 3.48 and 3.73-fold (IC90, from 57.33 to 16.48 µg/ml 374 
and IC95 from 70.36 to 18.84 µg/ml), indicating that a significant reduction of the doses of ZpE in 375 
the combination respective to the independent extract, is required for a complete inhibition of the 376 
fungus. From the point of view of LnE, IC50, IC80, IC90 and IC95 against C. albicans decreased 2.71, 377 
2.76, 2.83 and 2.89-fold respectively. 378 
Against C. glabrata, ZpE Feb within the combination, improved 1.85 and 1.86-fold the 379 
capability of 90 or 95% growth inhibition, compared to when acting on its own (IC90 and IC95 380 
decreased from 79.43 to 42.86 µg/ml and from 84.69 to 45.47 µg/ml respectively). Additionally, 381 
LnE Feb improved 6.02 and 7.83-fold the capability of inhibition of 90 or 95% of C. glabrata 382 
growth in combination with ZpE Feb, compared to when acting on its own (IC90 and IC95 of LnE 383 
decreased from 697.03 µg/ml and 960.28 µg/ml to 115.70 and 122.76 µg/ml respectively). 384 
Markers content in most synergistic mixtures 385 
Table 7 shows the concentrations of each marker in May and Feb mixtures at different effect 386 
levels (ϕ) against C. albicans and C. glabrata, respectively. 387 
INSERT TABLE 7 388 
Against C. albicans, the most synergistic ZpE-LnE mixture contains 8% of flavonoids 1-4 and 389 
36% of lignans 5-7. Within Zp markers, a predominance of 2,4-dihydroxychalcone 3 (4.5%) 390 
followed by 2,4-dihydroxy-3-methoxy chalcone 4 (2.6%) and pinocembrin 1 + galangin 2 (0.9%) 391 
was observed. Within Ln markers, a prevalence of MNDGA 7 (18%) followed by NDGA 5 (12%) 392 
and then DNDGA 6 (6%) was observed. However, although the proportion of markers are the same 393 
for all ϕ, the doses of the whole mixtures are different for achieving the different effects ϕ = 0.50, 394 
0.80, 0.90 and 0.95 (38.94, 49.91, 57.70 and 65.96 µg/ml respectively) (Fig. 6). Obviously, the 395 
dosis of 65.96 µg/ml for achieving a ϕ = 0.95 (95% inhibition of C. albicans) (with markers 396 
proportion described above) should be chosen for preparing a phytomedicine with activity against 397 
C. albicans infections. 398 
Against C. glabrata, ZpE-LnE the most synergistic mixture contains 9.7% of flavonoids 1-4 and 399 
31.6% of lignans 5-7. Within Zp markers, a predominance of 3 (4.7%) was observed, closely 400 
followed by 4 (4.4%) and with lower concentrations of 1 + 2 (0.90%). Within Ln markers, a 401 
prevalence of 7 (17%) followed by 5 (8%) and then 6 (7%) was observed. The whole combinations’ 402 
doses for achieving ϕ = 0.50, 0.80, 0.90 and 0.95 were 133.22, 148.69, 158.56 and 168.23 µg/ml, 403 
much higher that the doses needed for inhibiting C. albicans (Fig. 6). The dosis of 168.23 µg/ml 404 
(with the proportion of markers described above) for ϕ = 0.95 should be chosen when preparing a 405 
phytomedicine that is able to control C. glabrata infections. Fig. 6 comparatively shows the doses 406 
needed for inhibiting each fungus for all ϕ = 0.50, 0.80, 0.90 and 0.95. 407 
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INSERT FIG. 6 408 
It is clear that the dosis of the fixed ratio mixture of ZpE+LnE necessary to achieve the higher 409 
synergism at the best effect level ϕ = 0.95 against C. glabrata (168.23 µg/ml) is 2.55 times higher 410 
than the dosis required to inhibit C. albicans (65.96 µg/ml). The ratios between the amount of 411 
flavonoids markers 1-4, and lignans markers 5-7 will be 0.22 (5.39 µg/ml/23.63 µg/ml) against C. 412 
albicans and 0.30 (16.35 µg/ml/53.24 µg/ml) against C. glabrata, clearly showing that lignans are 413 
required in higher proportions than flavonoids against both fungi, although this difference is less 414 
pronounced when acting against C. glabrata.  415 
Declaration of herbal extracts and their most effective synergistic combination characteristics  416 
Considering that the most synergistic combinations are those that have an effect level ϕ = 0.95 417 
(95% fungal growth inhibition or higher), it can be declared that, in accordance to EMA guidelines 418 
(EMA 2010), each dosis (1 ml) of the most synergistic mixture against C. albicans, should contain 419 
65.96 µg of the whole mixture, composed of 18.84 µg of ZpE dry extract from Z. punctata Cav. 420 
aerial parts (9:1) and 47.12 µg of LnE dry extract from L. nitida Cav. aerial parts (12:1), 421 
corresponding to 5.39 µg of ZpE flavonoids markers and 23.63 µg of LnE lignans markers. In turn, 422 
each dosis (1 ml) of the most synergistic mixtures against C. glabrata should contain 168.23 µg of 423 
the whole mixture, composed of 45.47 µg of ZpE dry extract from Z. punctata Cav. aerial parts 424 
(8:1) and 122.76 µg of LnE dry extract from L. nitida Cav. aerial parts (10:1), corresponding to 425 
16.35 µg of ZpE flavonoids markers and 53.24 µg of LnE lignans markers. 426 
3D HPLC chromatograms 427 
The 3D HPLC profiles of the most synergistic mixtures against C. albicans (ZpE-LnE May) and 428 
C. glabrata (ZpE-LnE Feb) are shown in Fig. 7A and 7B respectively. This chromatogram was 429 
monitored at 254 nm, which allows to visualize both groups of compounds, lignans (λmax 280 nm) 430 
and flavonoids (λmax 267, 289 and 341 nm).  431 
INSERT FIG. 7 432 
Conclusions 433 
Synergism studies with the statistical-based MixLow method, allowed us to give support to the 434 
jointly use of ZpE and LnE in traditional medicine. As the results of this study, we could determine 435 
that 3 over 4 fixed-ratio mixtures, whose composition were estimated by a valid method, showed 436 
synergism against C. albicans while only one showed synergism against C. glabrata (at ϕ  0.5).  437 
Of them, one herbal-quantified ZpE-LnE preparation acting against C. albicans and one acting 438 
against C. glabrata are both of great interest for the development of an antifungal phytomedicine.  439 
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Table 1 
Identification data of markers 1-4 (ZpE) and 5-7 (LnE): Retention time (Rt), HRMS values and 
MS/MS fragments. Molecular Formulas (MF) and Molecular Weights (MW) are included. 
Markers Rt 
(min) 
MF MW HRMS (error in ppm) MS/MS fragments 
Feb May Sept Nov  
ZpE         
1 12.9 C15H10O5 270.05 269.0451 
(1.8) 
269.0457 
(-0.5) 
269.0446 
(3.7) 
269.0446 
(3.6) 
269.0451, 169.0653, 
171.0443, 195.0431, 
143.0496 
2 12.9 C15H12O4 256.07 255.0655 
(3.1) 
255.0656 
(2.7) 
255.0650 
(4.9) 
255.0649 
(4.9) 
255.0655, 227.0704, 
151.0033, 
123.0083,107.0145 
3 14.0 C15H12O3 240.08 239.0704 
(3.9) 
239.0709 
(1.9) 
239.0696 
(4.8) 
239.0703 
(4.7) 
239.0704, 197.0625, 
169.0606, 
148.0176,135.0100 
4 14.2 C16H14O4 270.09 269.0813 
(2.2) 
269.0814 
(1.9) 
269.0807 
(4.4) 
269.0812 
(2.6) 
269.0813, 254.0580, 
150.9983, 106.0055, 
94.0056 
LnE         
5 6.2 C18H22O4 302.15 337.1207 
(1.6) 
337.1204 
(2.5) 
337.1213  
(-0.3) 
337.1201 
(3.3) 
302.1470, 273.1486, 
122.0366 
6 9.6 C18H22O3 286.16 321.1256 
(2.0) 
321.1249 
(4.3) 
321.1253 
(3.1) 
321.1253 
(3.0) 
123.0407, 122.0366, 
108.0211 
7 10.1 C19H24O4 316.17 351.1366 
(0.8) 
351.1358 
(3.1) 
351.1362 
(1.9) 
351.1363 
(1.5) 
300.1357, 149.0596, 
135.0440, 122.0367 
The Rt was determined by three individual analysis (n=3). The detected compounds had the greatest responses under 
the negative mode and so, the M-H- was used as the precursor ion for 1-4, and M+Cl- for 5-8.  
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Table 2 
Linear regression data, precision, LOD and LOQ of compounds 1-5. 
Comp.  
(nm) 
Linear regression data  Precision, RSD (%) LOD 
(mg/ml) 
LOQ 
(mg/ml) 
  Regressive equation R2 Linear 
range 
(mg/ml) 
 Conc. 
(mg/ml) 
Intra-
day 
(n=3) 
Inter-
day 
(n=3) 
  
1 267 y=39148.63 x -2097.40 0.99 0.10-0.50  0.10 0.15 0.99 0.03 0.09 
      0.30 0.24 1.00   
      0.50 0.98 1.20   
2 289 y=33843.54 x -104.24 1.00 0.05-0.60  0.05 0.22 0.83 0.01 0.04 
      0.20 0.19 0.95   
      0.60 0.28 0.99   
3 341 y=9045.88 x -89.18 0.99 0.50-2.00  0.50 0.24 0.90 0.15 0.46 
      1.00 0.78 1.16   
      2.00 0.58 1.53   
4 341 y=10600.88 x -162.71 1.00 0.10-1.00  0.10 0.57 0.82 0.01 0.03 
      0.50 0.48 0.93   
      1.00 0.30 1.20   
5 280 y=4149.35 x -304.55 1.00 0.30-2.00  0.30 1.87 1.90 0.10 0.30 
      0.50 0.61 0.80   
      2.00 0.68 0.99   
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Table 3 
Quantitative assessment (g of compound /100 g extract) of the seven 
markers 1-7 in the four batches of each ZpE and LnE (of February, May, 
September and November of one year) by HPLC-UV method. Values 
are the mean ± Standard Deviation calculated from three replicates. 
Markers Feb May Sept Nov 
ZpE     
1 03.36 ± 0.01 03.10 ± 0.01 03.11 ± 0.01 03.26 ± 0.03 
2 03.36 ± 0.01 03.10 ± 0.01 03.11 ± 0.01 03.26 ± 0.03 
3 16.39 ± 0.05 15.93 ± 0.07 15.51 ± 0.09 16.54 ± 0.10 
4 16.22 ± 0.09 09.64 ± 0.06 15.15 ± 0.01 10.37 ± 0.21 
LnE     
5 10.39 ± 0.01 16.80 ± 0.05 12.48 ± 0.11 19.09 ± 0.08 
6 09.14 ± 0.02 08.53 ± 1.03 09.66 ± 0.02 10.24 ± 0.01 
7 23.84 ± 0.07 24.81 ± 0.10 27.37 ± 0.09 28.46 ± 0.02 
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Table 4  
IC50 values (µg/ml) of each extract alone obtained from the dose-response curves 
against C. albicans (Ca) and C. glabrata (Cg). For synergism studies, the ratio of 
concentrations tested (IC50 ZpE/IC50 LnE) is recorded. Each mixture was prepared 
from extract of the same period. 
Fungal 
strain 
Period 
IC50 ZpE 
(µg/ml). 
IC50 LnE 
(µg/ml). 
Ratio tested 
(IC50 ZpE/IC50 LnE) 
Ca 
Feb 27.33 ± 0.01 53.14 ± 0.02 0.51 
May 31.40  0.02 73.50  0.01 0.43 
Sept 31.90 ± 0.03 57.20 ± 0.01 0.56 
Nov 28.63 ± 0.01 36.88 ± 0.01 0.78 
Cg 
Feb 65.79 ± 0.01 271.70 ± 0.03 0.24 
May 66.47 ± 0.01 164.72 ± 0.01 0.40 
Sept 39.56 ± 0.01 152.16 ± 0.01 0.26 
Nov 58.73 ± 0.01 154.31 ± 0.01 0.38 
Amphotericin B was used as standard drug: IC50 against C. albicans = 0.25 µg/ml; against C. 
glabrata = 0.25 µg/ml. 
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Table 5 
Lϕ values (combination indexes) and confidence intervals and type of interaction of the mixtures ZpE-LnE from different months of a year, 
against C. albicans (Ca) and C. glabrata (Cg) at fractions affected (ϕ) = 0.50, 0.80, 0.90 and 0.95 (inhibitory percentages 50, 80, 90 and 95 
%). 
Fungal 
strain 
Combination 
Lϕ values at 
ϕ (inhibition percentage) 
0.50 (50%) Int (clasif) 0.80 (80%) Int (clasif) 0.90 (90%) Int (clasif) 0.95 (95%) 
Int 
(clasif) 
Ca 
ZpE-LnE Feb 0.92 ± 0.02 Ad (n) 0.96 ± 0.02 Ad (n) 0.99 ± 0.03 Ad (n) 1.01 ± 0.04 Ad (n) 
ZpE-LnE May 0.73 ± 0.01 S (m) 0.68 ± 0.02 S (med) 0.65 ± 0.03 S (med) 0.62 ± 0.04 S (med) 
ZpE-LnE Sept 0.95 ± 0.02 Ad (n) 0.77 ± 0.02 S (m) 0.71 ± 0.03 S (m) 0.67 ± 0.04 S (med) 
ZpE-LnE Nov 0.89 ± 0.01 S (sl) 0.88 ± 0.01 S (sl) 0.87 ± 0.02 S (sl) 0.87 ± 0.02 S (sl) 
Cg 
ZpE-LnE Feb 0.91 ± 0.01 Ad (n) 0.77 ± 0.02 S (m) 0.71 ± 0.02 S (m) 0.67 ± 0.02 S (med) 
ZpE-LnE May 0.98 ± 0.01 Ad (n) 1.00± 0.01 Ad (n) 1.03 ± 0.02 Ad (n) 1.05 ± 0.02 Ad (n) 
ZpE-LnE Sept 1.21 ± 0.01 An (m) 1.13 ± 0.01 An (sl) 1.09 ± 0.02 Ad (n) 1.06 ± 0.02 Ad (n) 
ZpE-LnE Nov 1.20 ± 0.01 An (m) 1.15 ± 0.01 An (sl) 1.12 ± 0.02 An (sl) 1.09 ± 0.02 Ad (n) 
Int: type of interaction; Clasif: classification of Synergism (S), Antagonism (An) and Additivism (Ad) in: slight (sl), moderate (m), medium (med), (n): near. Ca: C. 
albicans CCC 125; Cg: C. glabrata CCC 115. 
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Table 6 
ICx (Inhibitory Concentration to achieve X% of effect) of ZpE and LnE alone and in the May or February combination against C. albicans (Ca) 
and C. glabrata (Cg) respectively, and DRI values, at ϕ = 0.5, 0.8, 0.90 and 0.95 (inhibitory percentages 50, 80, 90 and 95%). 
  I II III (= IV+V) IV V VI 
VII 
(I/IV) 
VIII 
(II/V) 
Fungal 
strain 
ϕ (X% effect) 
ICx ZpE 
alone 
(µg/ml) 
ICx LnE 
alone 
(µg/ml) 
ICx ZpE + ICx LnE 
in the combination 
(µg/ml) 
ICx ZpE 
in the 
combination 
(µg/ml) 
ICx LnE 
in the combination 
(µg/ml) 
Lϕ = CI 
DRI 
ZpE 
DRI LnE 
Ca 
0.50 (50%) 31.40 73.50 38.94 11.80 27.14 0.73±0.01 2.66 2.71 
0.80 (80%) 45.91 98.28 49.91 14.26 35.65 0.68±0.02 1.29 2.76 
0.90 (90%) 57.33 116.48 57.70 16.48 41.22 0.65±0.03 3.48 2.83 
0.95 (95%) 70.36 136.22 65.96 18.84 47.12 0.62±0.03 3.73 2.89 
Cg 
0.50 (50%) 65.79 271.70 133.22 26.12 107.09 0.91±0.01 2.52 2.54 
0.80 (80%) 74.09 492.32 148.69 40.19 108.50 0.77±0.02 1.84 4.54 
0.90 (90%) 79.43 697.03 158.56 42.86 115.70 0.71±0.02 1.85 6.02 
0.95 (95%) 84.69 960.28 168.23 45.47 122.76 0.67±0.24 1.86 7.83 
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Table 7 
Concentrations (µg/ml) of markers 1-7 in the most synergistic ZpE-LnE mixtures against C. albicans and C. glabrata respectively, at 
different ϕ. 
ϕ 1 + 2 3 4 
Total ZpE 
flavonoids 
5 6 7 
Total LnE 
lignans 
Whole 
mixture 
ZpE-LnE best synergistic mixture (May) against C. albicans 
0.50 0.34  0.03 1.77  0.02 1.07  0.01 3.18 (8%) 4.67  0.01 2.37  0.04 6.90  0.03 13.94 (36 %) 38.94 
0.80 0.44  0.02 2.27  0.01 1.37  0.01 4.08 (8%) 5.99  0.02 3.04  0.04 8.85  0.04 17.88 (36%) 49.91 
0.90 0.51  0.02 2.63  0.01 1.58  0.05 4.72 (8%) 6.92  0.02 3.52  0.03 10.23  0.04 20.67 (36 %) 57.70 
0.95 0.58  0.01 3.00  0.04 1.81  0.02 5.39 (8%) 7.92  0.03 4.02  0.05 11.69  0.05 23.63 (36 %) 65.96 
ZpE-LnE best synergistic mixture (Feb) against C. glabrata 
0.50 1.28  0.02 5.84  0.03 5.80  0.03 12.92 (9.7 %) 10.12  0.01 8.92  0.02 23.04  0.08 42.15 (31.6 %) 133.22 
0.80 1.35  0.02 6.57  0.03 6.52  0.02 14.44 (9.7 %)  11.27  0.02 9.92  0.02 25.86  0.10 47.05 (31.6 %) 148.69 
0.90 1.44  0.01 7.01  0.01 6.96  0.04 15.41 (9.7%)  12.02  0.01 10.58  0.01 27.58  0.10 50.18 (31.6 %) 158.56 
0.95 1.53  0.01 7.44  0.02 7.38  0.04 16.35 (9.7%)  12.75  0.03 11.23  0.01 29.26  0.09  53.24 (31.6 %) 168.23 
Markers of ZpE are: 1 (galangin), 2 (pinocembrin), 3 (2´,4´-dihydroxychalcone) and 4 (2´,4´-dihydroxy-3´-methoxychalcone). Markers of LnE are: 5 (NDGA), 6 (DNDGA) 
and 7 (MNDGA). Compounds 1 and 2 had same Rt, so they could not quantify separately. 
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Scheme 1. Whole process of MixLow method: (a) Preparation of three dose-response curves: (a1) 
one curve for each extract alone, confectioned with the data of each extract (ZpE and LnE). 
Estimation of parameter values; (a2) Preparation of a dose-response curve for a fixed-ratio mixture of 
both extracts. Estimation of parameter values. (b) Use estimated parameters in calculating the Loewe 
Index (Lϕ). (c) Generation of confidence intervals for Lϕ, and obtaining an Affected fraction vs Lϕ 
graph. 
Fig. 1. Isolated compounds from ZpE (1-4), and for LnE (5-7). 
Fig. 2. Design of a 96-well microplate used for analysis of antifungal activity of the extracts alone 
and mixtures. 
Fig. 3. HPLC-UV chromatograms of four batches of each Zuccagnia punctata extract (ZpE) (left) at 
254 nm and Larrea nitida extract (LnE) (right) at 280 nm. Marker compounds of ZpE and their 
Retention times (Rt, min) are: 5,7-dihydroxy-3-flavonol (galangin 1) 12.9 min; 5,7-dihydroxy 
flavanone (pinocembrin 2) 12.9 min; 2’,4’-dihydroxychalcone (3) 14.0 min; 2’,4’-dihydroxy-3’-
methoxy chalcone (4) 14.2 min. Marker compounds of LnE and their Rt are: nordihydroguairetic 
acid (NDGA 5) 6.2 min; 4-[4-(4-hydroxyphenyl)-2,3-dimethyl-butyl]-benzene-1,2-diol (DNDGA 6) 
9.6 min; 3’-methyl nordihydroguiaretic acid (MNDGA 7) 10.1 min. 
Fig. 4. (A-D): Dose-response curves of single and combined ZpE and LnE, prepared with plants 
collected in four periods of one year against C. albicans. Mixtures ZpE-LnE were tested at the fixed 
ratio IC50ZpE/IC50LnE at 10 equi-spaced concentrations in the ln scale. (A’-D’): Affected fraction () 
vs Estimated Loewe Index (L) (full line) with 95% confidence interval (dotted lines). Full line at L 
= 1 represents additivity line. Lines below or above the additivity show synergism or antagonism, 
respectively.  
Fig. 5. (A-D): Dose-response curves of single and combined ZpE and LnE, prepared with plants 
collected in four periods of one year against C. glabrata. Mixtures ZpE-LnE were tested at the fixed 
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ratio IC50ZpE/IC50LnE at 10 equi-spaced concentrations in the ln scale. (A’-D’): Affected fraction () 
vs Estimated Loewe Index (L) curves (full line) with 95% confidence interval (dotted lines). Full 
line at L = 1 represents additivity. Lines below or above L = 1 denote synergism or antagonism, 
respectively. 
Fig. 6. Doses of the whole synergistic ZpE-LnE combinations and their content in marker 
compounds for achieving an effect level ϕ = 0.50, 0.80, 0.90 and 0.95 against C. albicans and C. 
glabrata. 
Fig. 7. 3D-HPLC profile of the two-herbal combination formed by Z. punctata and L. nitida in the 
concentration that produces 95% of growth inhibition. The representative peaks of the markers of 
both herbs were indicated. Peaks number 1-4 belong to Z. punctata and peaks number 5-7 belong to 
L. nitida. (A) ZpE-LnE mixture of May. (B) ZpE-LnE mixture of February. Detection was at 254 nm. 
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Scheme 1 
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Fig. 6 
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Fig. 7 
 
